Physician profile
Rita E Eye
NPI 1437370681
$4,808.22
in general payments reported to CMS, 2019-2025
33 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $68.17 · 2021: $155 · 2022: $313 · 2023: $2,203 · 2024: $424 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Consulting Fee: $1,200 · Food and Beverage: $781 · Travel and Lodging: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Consulting Fee | $1,200.00 |
| Food and Beverage | $780.68 |
| Travel and Lodging | $355.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,927.49 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Mimedx Group, INC. | $1,200.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $151.93 | 2019-2025 | |
| Exeltis, USA INC. | $136.80 | 2022-2025 | Slynd |
| Astellas Pharma US INC | $124.33 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $109.47 | 2021-2023 | |
| Organon LLC | $101.15 | 2022-2025 | Nexplanon |
| Pacira Pharmaceuticals Incorporated | $100.00 | 2019 | |
| Smith+Nephew, INC. | $97.69 | 2019 | |
| Hologic Sales and Service, LLC | $96.95 | 2019-2023 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $80.36 | 2020-2022 | |
| Agile Therapeutics, INC. | $78.39 | 2021-2023 | Twirla |
| Coopersurgical, INC. | $72.04 | 2022-2025 | Sos, Mara Console |
| Allergan, INC. | $62.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.20 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $45.75 | 2024 | Myfembree |
| Novo Nordisk INC | $38.62 | 2019 | |
| Mylan Pharmaceuticals INC. | $36.04 | 2019-2021 | |
| Meditrina | $29.52 | 2022-2024 | |
| Radiometer America, INC | $26.39 | 2025 | |
| Siemens Medical Solutions USA, INC. | $22.43 | 2023 | Mammomat Revelation |
| Asensus Surgical, INC. | $21.31 | 2022 | |
| Pfizer INC. | $21.05 | 2022 | |
| Evofem Biosciences, INC. | $20.60 | 2021 | |
| Gynesonics, INC. | $19.87 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Solta Medical, A Division of Bausch Health US, LLC | $19.48 | 2024 | Clear & Brilliant |
| Millicent US INC | $17.04 | 2019 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Shield Therapeutics INC | $16.10 | 2025 | |
| Daiichi Sankyo INC. | $15.41 | 2019 | |
| Guard Medical INC. | $14.70 | 2023 | Npseal Medium, Npseal (5), Npseal Large |
| Merck Sharp & Dohme LLC | $14.35 | 2020 | |
| Avion Pharmaceuticals | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Eye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.